SAB Biotherapeutics Sees Positive Results from COVID Drug SAB-185

SAB Biotherapeutics Sees Positive Results from COVID Drug SAB-185

By Exec Edge Editorial Staff SAB Biotherapeutics (Nasdaq: SABS) said it saw positive results from a Phase 3 clinical trial that assessed its Covid-19 drug, SAB-185, in non-hospitalized people who were at high-risk for severe outcomes. SAB-185 demonstrated benefit in...

FullBeauty Brands to Acquire Plus-Size Brand ELOQUII

FullBeauty Brands to Acquire Plus-Size Brand ELOQUII

By Exec Edge Editorial Staff FullBeauty will acquire plus-size fashion authority ELOQUII Inc. from Walmart, it said in a statement. The acquisition will allow FullBeauty to expand its presence in the $81 billion women’s plus-sized sector in the U.S. ELOQUII...

reAlpha Launches Fractional Ownership Platform for Short-Term Rentals

reAlpha Launches Fractional Ownership Platform for Short-Term Rentals

    By Exec Edge Editorial Staff Real estate technology company reAlpha said it launched its fractional ownership platform for global short-term rentals. The platform allows accredited and non-accredited investors to add vacation rentals to their investment portfolios through “initial...

Lunaphore Raises CHF40M in Series D Funding For Spatial Biology

Lunaphore Raises CHF40M in Series D Funding For Spatial Biology

By Daniella Parra Lunaphore said it completed CHF40 million in Series D1 funding led by Ernst-Göhner Stiftung Beteiligungen (EGSB). The Swiss life sciences company said it plans to use the funding to strengthen its portfolio offering in spatial biology and support...

Input your search keywords and press Enter.